TO THE EDITOR:
We were very interested in the recent article by Hameed et al. published in Liver Transplantation. (1) In this article, the authors performed a study aimed at looking for the effects of the perfusion route (aortic or dual) and of the preservation solution on the graft outcome following liver transplantation. They concluded that there is no sufficient evidence to justify a preference either for the route or for the solution. Because of the potential clinical relevance of this conclusion, we would like to raise the following questions.
Was This Meta-Analysis Able to Obtain a Good Scientific Comparison of Preservation Solutions?
From 56 full-text articles assessed for eligibility, 22 studies could be included in the qualitative synthesis, and only 14 with quantitative syntheses were finally included in the meta-analysis. However, 1. The judgment criteria were different among the selected articles. 2. The evaluated solutions were different from 1 study to another. 3. To compare preservation solutions, only 2 metaanalyses could be performed: a. Between histidine-tryptophan-ketoglutarate (HTK) and University of Wisconsin (UW) dual perfusion with peaks of aspartate aminotransferase and alanine aminotransferase as an endpoint, but without any information on graft survival; b. Between UW versus Celsior dual perfusion with a moderate-quality study.
No meta-analysis and no other statistical comparisons could be made to compare graft survival between the 4 main preservation solutions (UW, HTK, Institut Georges Lopez [IGL] 1, and Celsior). In relation to this assessment comes the second more important question.
What Is the Clinical Relevance of the Results of This Meta-Analysis?
As reported by the authors, the low quality, the missing factors, and the limited number of patients of the included articles implied an evident lack of power to conclude any difference. However, their conclusions of insufficient evidence to advocate for the use of any particular preservation fluid offered 2 possible interpretations:
1. All the solutions could continue to be used without an impact on graft outcome. 2. The absence of proof from these selected studies does not mean an absence of difference.
Then we come to the third question. The authors have analyzed in summary 2294 liver grafts from 22 articles with all the mentioned inconsistencies, and they did not take into account the European Liver Transplant Registry (ELTR) results of 42,869 preserved liver grafts in Europe, (2) which is a study that was confirmed by a further propensity score-matched analysis comparing 4964 HTK-preserved versus 9928 UW-Celsior-IGL1-preserved liver grafts, (3) both showing that HTK was an independent risk factor of graft loss. They took no more consideration to the 17,428 preserved liver grafts in the United States (4755 with HTK versus 12,673 with UW) showing that after adjusting for donor, recipient, and graft factors, HTK preservation was associated with an increased risk of graft loss. (4) Although complaining about the overall quality of the selected articles, the authors missed including the converging results of more than 60,000 transplantations in Europe and the United States by ELTR and United Network for Organ Sharing data in these syntheses. By doing that, the authors would have probably been more nuanced in their conclusion of "no difference," a conclusion which is very questionable because of the lack of power and because of the suboptimal quality of their selected articles. 
